Skip to content

Alkermes ALKS Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
10.9%-9.2pp
AbbVie logo
AbbVieABBV
5.2%+1.0pp
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-0.8%-0.3pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-11.6%+15.9pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
6.3%+1.8pp

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Calculated from Alkermes’s reported figures.

Based on trailing twelve months.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's free cash flow yield?
Alkermes (ALKS) reported free cash flow yield of 3.8% in Q1 2026.
How has Alkermes's free cash flow yield changed year-over-year?
Alkermes's free cash flow yield decreased by 58.0% year-over-year, from 9% to 3.8%.
What is the long-term trend for Alkermes's free cash flow yield?
Over 5 years (2020 to 2025), Alkermes's free cash flow yield has grown at a 52.5% compound annual growth rate (CAGR), from 1.3% to 10.4%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.